You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. High-Resolution, Spinal Cord Stimulation for Non-Opioid Treatment of Neuropathic Pain

    SBC: Micro-Leads, Inc.            Topic: 106

    Abstract DESCRIPTION. In this SBIR FastTrack proposal, Micro-Leads will develop HD64—a high-resolution, 64- channel spinal cord stimulation therapy to provide more pain relief with greater specificity for those suffering from chronic neuropathic pain and opioid dependence. Over 25 million in the U.S. suffer from debilitating pain in the trunk and extremities and 55% depend on opioids to ease the ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB

    SBC: CELLF-BIO, LLC            Topic: 300

    Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. IND-enablingEpicardial Biopharmaceutical in the Diabetic Heart

    SBC: Regencor, Inc.            Topic: NHLBI

    ABSTRACT Diabetes mellitus (DM) is caused by inadequate insulin secretion or an inability to respond appropriately to secreted insulin, which leads to chronic elevated blood sugar levels (hyperglycemia). An estimated 171 million people worldwide have DM, and the prevalence of DM will more than double over the next 2 decades. Diabetic patients have increased rates, severity, and complexity of ather ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Long-acting PTH for hypoparathyroidism

    SBC: Extend Biosciences Inc.            Topic: NIDDK

    Project Summary Hypoparathyroidism is a rare disease that results from a deficiency or inability to make sufficient amounts of parathyroid hormonePTHUntreated or inadequately treated hypoparathyroidism leads to clinically significant mineral related metabolic issues including hypocalcemiawhich leads to heart arrhythmiasspasms of the vocal cordsand seizuresCurrent management of the disease for the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease

    SBC: Cenna Biosciences Inc.            Topic: NIA

    SummaryThe parent Commercialization Readiness Program grant was to conduct studies necessary to support regulatory submissions relating to pre-clinical development of Cenna’s peptide drug candidate mP8. mP8 is being developed as a new, first-in-class peptide drug for the treatment of Alzheimer’s disease. The funded grant builds on the substantial progress made under the previously funded SBIR ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. TDP-43 aggregation inhibitors for the treatment of ALS

    SBC: Aquinnah Pharmaceuticals Inc.            Topic: 105

    Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging and Ureter Mapping

    SBC: Curadel, LLC            Topic: 102

    Image-guided surgery using invisible near-infrared (NIR) fluorescent light is here to stay. Multiple commercial imaging systems from Stryker, Olympus, Medtronic, and Intuitive Surgical are now available for human surgery. However, only innovative NIR fluorophores will solve major clinical problems.Curadel has invented a novel family of NIR fluorophores termed “zwitterionic,” or more precisely, ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer

    SBC: PRIVO TECHNOLOGIES, LLC            Topic: NCI

    Preceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of PAR2 Pepducins as a Novel NASH Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: 300

    Non alcoholic steatohepatitisNASHis characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosiscirrhosis and high mortality ratesNASH is frequently associated with other common metabolic abnormalitiessuch as insulin resistance and visceral obesityLiver transplantation is currently the only effective therapeutic approach for seve ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Evaluation of NoGo Trap Therapy in Chronic SCI

    SBC: ReNetX Bio, Inc.            Topic: NINDS

    Summary Approximately 300,000 patients suffer from persistent neurological impairment due to chronic spinal cord injury (SCI) in the United States. Currently, there are no FDA-approved drugs to promote neurologic recovery in patients suffering from the life-long, profound impairments due to chronic SCI. An effective neurorestorative therapy would significantly improve the ability of patients to co ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government